Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17015941 | 0.94 | KDM4E (0.35) | KDM4EATML3MBTL1TSHRBCHE | |
| SCHEMBL17015938 | 0.91 | L3MBTL1 (0.38) | KDM4EATML3MBTL1TSHRAPP | |
| SCHEMBL17015858 | 0.88 | KDM4E (0.35) | KDM4EATML3MBTL1TSHR | |
| SCHEMBL17015945 | 0.86 | KDM4E (0.47) | KDM4EATML3MBTL1TSHRBCHE | |
| SCHEMBL17015920 | 0.86 | KDM4E (0.34) | KDM4EATML3MBTL1 | |
| SCHEMBL17015935 | 0.85 | L3MBTL1 (0.41) | KDM4EATML3MBTL1TSHRBCHE | |
| SCHEMBL17015919 | 0.84 | KDM4E (0.33) | KDM4EATML3MBTL1TSHR | |
| SCHEMBL17016105 | 0.82 | L3MBTL1 (0.35) | KDM4EATML3MBTL1 | |
| SCHEMBL17015384 | 0.81 | KDM4E (0.33) | KDM4EATML3MBTL1BCHEACHE | |
| SCHEMBL17016257 | 0.81 | KDM4E (0.35) | KDM4EATML3MBTL1BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9837618-B2 | Compound and organic electroluminescence device including thesame | DOOSAN CORPORATION (KR) | 2017-12-05 | — | — | US | disclosed |
| US-9837618-B2 | Compound and organic electroluminescence device including thesame | DOOSAN CORPORATION (KR) | 2017-12-05 | — | — | US | disclosed |
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | DOOSAN CORPORATION (KR) | 2015-08-20 | — | — | US | disclosed |
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | DOOSAN CORPORATION (KR) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150236272-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME | INMT, IDO1, IDO2 | KDM4E 1286/4885ATM 3623/4885L3MBTL1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.